Sandoz has set ambitious long-term targets for its biosimilar business, according to analysts at "ZertifikateJournal" writing in their latest issue. At its capital markets day, the generics manufacturer presented a strategy dubbed "Bio100," under which it plans to expand its biosimilar portfolio from the current 13 products to 100 by 2040. Net revenue should more than double between 2025 and 2035.
Biosimilars are considered more margin-rich than classic generics and benefit from a growing number of expiring patents, making Sandoz's positioning well-suited to a market with substantial long-term growth potential. Management already aims for annual revenue growth in the mid-to-high single-digit percentage range through 2030.
However, several risks remain. Potential U.S. import tariffs are creating uncertainty for the company's global operations. While Sandoz is relatively well-positioned with its worldwide production footprint, the impact on supply chains and margins remains difficult to quantify. Patent disputes, routine in the biosimilar sector, could delay product launches and generate additional costs.
